Entrectinib, a next-generation TKI, received FDA approval for ROS1-positive NSCLC based on the results from the STARTRK-2 trial, where it demonstrated an ORR of 77% and a median PFS of 19.0 months. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.